OMass Therapeutics

The company’s pipeline includes small molecules targeting membrane proteins and intracellular complexes like Solute Carriers, GPCRs, and Inflammasome, with a focus on immunological and orphan diseases.

The company studies protein interactions in their native environment to understand fundamental biological processes.

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

OMass develops medicines to treat immunological and orphan diseases, supported by investors aligned with its mission.

The company researches new drugs for orphan and immunological diseases.

Interrogating not just the target but how it interacts with its native ecosystem

OMass Therapeutics secures **$310 million in Series C funding** to develop small-molecule drugs targeting **endocrinology and immunology**. The round is co-led by **Bain Capital Life Sciences, Forbion, and Novo Holdings**, alongside existing and new investors. The capital will accelerate clinical-stage programs in its therapeutic pipeline.

Oct 2026markets.businessinsider.comNews article

OMass Therapeutics secures $310 million in Series C funding to develop small-molecule treatments for endocrinology and immunology. The round supports a pipeline including a potential therapy for congenital adrenal hyperplasia, positioning the company to compete with Vertex and Neurocrine Biosciences. The Oxford-based biotech advances its drug development efforts with the largest financing round in Europe this year.

Oct 2026European Biotechnology MagazineNews article